151 related articles for article (PubMed ID: 12079295)
1. Effect of fenretinide on ovarian carcinoma occurrence.
De Palo G; Mariani L; Camerini T; Marubini E; Formelli F; Pasini B; Decensi A; Veronesi U
Gynecol Oncol; 2002 Jul; 86(1):24-7. PubMed ID: 12079295
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
[TBL] [Abstract][Full Text] [Related]
3. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
[TBL] [Abstract][Full Text] [Related]
4. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro MG; Costa A; Marubini E; Sporn MB; De Palo G
Ann Oncol; 2006 Jul; 17(7):1065-71. PubMed ID: 16675486
[TBL] [Abstract][Full Text] [Related]
5. Fenretinide and risk reduction of second breast cancer.
Decensi A; Zanardi S; Argusti A; Bonanni B; Costa A; Veronesi U
Nat Clin Pract Oncol; 2007 Feb; 4(2):64-5. PubMed ID: 17259924
[No Abstract] [Full Text] [Related]
6. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
[TBL] [Abstract][Full Text] [Related]
7. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
[No Abstract] [Full Text] [Related]
8. Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Piantadosi S
J Natl Cancer Inst; 1999 Nov; 91(21):1794. PubMed ID: 10547379
[No Abstract] [Full Text] [Related]
9. Fenretinide and cancer prevention.
Torrisi R; Decensi A
Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
[TBL] [Abstract][Full Text] [Related]
10. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
[TBL] [Abstract][Full Text] [Related]
11. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
12. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
13. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
Ann N Y Acad Sci; 1995 Sep; 768():148-62. PubMed ID: 8526344
[No Abstract] [Full Text] [Related]
14. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer prevention trials using retinoids.
Decensi A; Serrano D; Bonanni B; Cazzaniga M; Guerrieri-Gonzaga A
J Mammary Gland Biol Neoplasia; 2003 Jan; 8(1):19-30. PubMed ID: 14587861
[TBL] [Abstract][Full Text] [Related]
16. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer with fenretinide.
Veronesi U; De Palo G; Costa A; Formelli F; Decensi A
IARC Sci Publ; 1996; (136):87-94. PubMed ID: 8791119
[No Abstract] [Full Text] [Related]
18. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
Cassano E; Coopmans de Yoldi G; Ferranti C; Costa A; Mascotti G; De Palo G; Veronesi U
Eur J Cancer; 1993; 29A(15):2161-3. PubMed ID: 8297658
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
20. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia.
De Palo G; Veronesi U; Marubini E; Camerini T; Chiesa F; Nava M; Formelli F; Del Vecchio M; Costa A; Boracchi P
J Cell Biochem Suppl; 1995; 22():11-7. PubMed ID: 8538187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]